Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Zoetis

Why Zoetis, Fluffy's Drugmaker, Just Reversed Its Recent Bad Fortune

Zoetis stock reversed its recent bad fortune Thursday, rising after the pet-drug maker beat first-quarter expectations.

Investors Business Daily

Zoetis Stock Crumbles After Report Suggests Arthritis Shots Sickened Dogs, Cats

Zoetis stock crumbled Friday after a report suggested the company's arthritis shots, Librela and Solensia, could have sickened dogs and cats.

Investors Business Daily

How To Painlessly Put Together A Profitable POWR Pairs Trade

Using the POWR Ratings to power profits on a POWR Pairs trade in Zoetis (ZTS) and Air Products (APD).

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Victoria seals deal worth up to $350m for old CSL site

The Victorian government has purchased the former CSL site in Melbourne's inner north and on-sold part of the land to an animal vaccine giant.

AAP

Zoetis (ZTS): Analyzing Earnings for Potential Gains

Veterinary drugmaker Zoetis Inc. (ZTS) is all set to disclose its fiscal fourth-quarter earnings tomorrow. With the company boasting an impressive track record of consistently surpassing earnings expectations, would it be wise to acquire the shares of ZTS ahead of its earnings? Keep reading to find out….

StockNews.com

Zoetis Stock Rising — A Good Addition For Your Portfolio?

Zoetis stock shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

3 Buy-Rated Healthcare Dividend Stocks for Income Investors

Looking for analysts' favorite stock picks in a traditionally defensive sector, with solid dividend payments to help boost your returns? Here's a look at three stocks for income investors to consider at current levels.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Kevin O’Leary’s net worth: 'Shark Tank' investments, businesses, & more

"Mr. Wonderful" Kevin O'Leary is the toughest sell on 'Shark Tank'–but how did he make his fortune, and what is he worth now?

The Street

Management consultants can make great CEOs—but they have to get their hands dirty first

Some 47 Fortune 500 CEOs have spent time as management consultants but first took more junior roles.

Fortune

Market Rally On The Ropes, AI Stocks Tumble: Weekly Review

The market rally suffered more damage as the Nasdaq undercut key support and many leading AI stocks sold off hard.

Investors Business Daily

Drugmaker Zoetis Stock Shows Rising Relative Strength

A Relative Strength Rating upgrade for Zoetis shows improving technical performance.

Investors Business Daily

Spot's Drugmaker, Zoetis, Digs Up A Breakout On Its Second-Quarter Beat

Zoetis trimmed its sales outlook Tuesday, but ZTS stock reversed a premarket dip and climbed on the easy second-quarter beat.

Investors Business Daily

Drug Maker Zoetis Stock Scores Relative Strength Upgrade

Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Stock Market Holds Gains As Dow Keeps Run Going; Airline Stock Flashes Sell Signal

The Dow Jones notches a gain for the 12th day in a row. But airline stocks had a bumpy ride.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

Zoetis's Wetteny Joseph—one of the few Black CFOs in the Fortune 500—began his journey to finance chief in Haiti

Joseph shares his personal journey, discusses why representation matters, and explains what specific steps landed him in the C-suite.

Investors Business Daily

Spot's Drugmaker Claws Back Into The Green Despite Slowing Pet Sales

Animal health behemoth Zoetis posted an unusual first quarter, an analyst said Thursday after ZTS stock clawed back from a premarket dive.

Investors Business Daily

Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens

A Relative Strength Rating upgrade for Zoetis stock shows improving technical performance. Will it continue?

Investors Business Daily

Zoetis Stock Sees IBD Relative Strength Rating Improve To 73

A Relative Strength Rating upgrade for Zoetis shows improving technical performance. Will it continue?

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Zoetis Stock Shows Rising Relative Strength Upgrades

Zoetis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Investors Business Daily

Zoetis Fetches A Quarterly Beat And Shares Surge To A Six-Month High

Animal health giant Zoetis beat fourth-quarter sales expectations Tuesday and issued a strong 2023 sales outlook, leading ZTS stock to pop.

Investors Business Daily

Mutual Funds Are Investing In 'Survivors' For 2023

Stock picking is an art in a tough market. Learn which companies mutual fund managers believe can grow during economic uncertainty.

Fortune

Top executives explain how they achieve ESG goals amid backlash

How should companies reframe ESG initiatives amid controversy? These executives offer their strategies.

Fortune

I asked the world’s top CEOs if they’re taking diversity seriously. Here’s why their answers could change your life

Corporate culture has entered the fourth phase in its history: the integration of purpose and profit, writes Robert Reiss.

Investors Business Daily

Zoetis Stock Yelps As Animal-Health Giant Hacks $200 Million-Plus Off Its Outlook

Zoetis trimmed its 2022 outlook on Thursday after the animal-health company missed third-quarter forecasts. ZTS stock tumbled.

Investors Business Daily

Fluffy's Drugmaker Trims 2022 Outlook As Livestock Sales Continue To Dive

Fluffy's drugmaker Zoetis offered a mixed second-quarter report Thursday, pushing ZTS stock to sink in early action.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.